Enzymatica
Lund
About Enzymatica
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. Since launch the product has become one of the leading articles for colds in Swedish pharmacies. Development includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $17.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2024)
- Ticker: sto:ENZY
- Website: enzymatica.com
- Phone: +46 20 14 20 15
Industries & Categories
Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/enzymatica-12436 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.